{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:08:30Z","timestamp":1787170110657,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.phrs.2017.11.013","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T14:17:18Z","timestamp":1510582638000},"page":"265-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases"],"prefix":"10.1016","volume":"135","author":[{"given":"Keiran S.M.","family":"Smalley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2017.11.013_bib0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/bjc.2014.476","article-title":"Beyond BRAF: where next for melanoma therapy?","volume":"112","author":"Fedorenko","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"26","key":"10.1016\/j.phrs.2017.11.013_bib0010","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9829","key":"10.1016\/j.phrs.2017.11.013_bib0015","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.phrs.2017.11.013_bib0020","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2017.11.013_bib0025","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"20","key":"10.1016\/j.phrs.2017.11.013_bib0030","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.11.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Overall survival for dabrafenib and trametinib versus dabrafenib and placebo in V600 BRAF-mutant melanoma: a multi-center, double-blind, phase 3 randomised controlled trial","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"8 Suppl","key":"10.1016\/j.phrs.2017.11.013_bib0040","article-title":"Preclinical profile of LG: a potent and selective RAF kinase inhibitor","volume":"72","author":"Stuart","year":"2012","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2017.11.013_bib0045","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pcmr.12538","article-title":"Melanoma central nervous system metastases: current approaches, challenges, and opportunities","volume":"29","author":"Cohen","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"10.1016\/j.phrs.2017.11.013_bib0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2017.11.013_bib0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2017.11.013_bib0060","article-title":"p-glycoprotein (MDR1\/ABCB1) and Breast Cancer Resistance Protein (BCRP\/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice","author":"Wang","year":"2017","journal-title":"Pharm. Res."},{"issue":"7","key":"10.1016\/j.phrs.2017.11.013_bib0065","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2017.11.013_bib0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cam4.50","article-title":"Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases","volume":"2","author":"Niessner","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.phrs.2017.11.013_bib0075","article-title":"Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies","author":"Sloot","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2017.11.013_bib0080","doi-asserted-by":"crossref","first-page":"e67583","DOI":"10.1371\/journal.pone.0067583","article-title":"Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions","volume":"8","author":"King","year":"2013","journal-title":"PLoS One"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817314512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817314512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T20:47:01Z","timestamp":1536612421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817314512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":16,"alternative-id":["S1043661817314512"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.11.013","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}